DCT

2:26-cv-04121

Takeda Pharmaceutical Co Ltd v. Qilu Pharmaceutical Hainan Co Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-04121, D.N.J., 04/17/2026
  • Venue Allegations: Plaintiff Takeda alleges venue is proper in the District of New Jersey because Defendant Qilu conducts business throughout the United States, including New Jersey, and the district is a likely destination for the accused generic product. The complaint also asserts that Qilu has previously stipulated to or otherwise availed itself of personal jurisdiction in this district in prior patent cases.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for approval to market a generic version of Plaintiff's LIVTENCITY® (maribavir) tablets constitutes an act of patent infringement.
  • Technical Context: The technology relates to compositions of the antiviral drug maribavir, specifically claiming formulations with low levels of certain synthesis-related impurities, and improved methods for its manufacture.
  • Key Procedural History: This is a Hatch-Waxman action initiated in response to Defendant Qilu's submission of ANDA No. 221142 with a Paragraph IV certification, challenging the patent-in-suit. The complaint was filed within 45 days of Takeda's receipt of Qilu's notice letter, triggering a potential 30-month stay of FDA approval for Qilu's ANDA. The complaint also notes other related litigations Takeda has filed against other generic manufacturers for the same drug product.

Case Timeline

Date Event
2022-10-12 '771 Patent Priority Date
2026-01-20 '771 Patent Issue Date
2026-03-26 Qilu sends Paragraph IV Notice Letter to Takeda
2026-04-17 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,527,771

  • Patent Identification: United States Patent No. 12,527,771, Viral Inhibitors, The Synthesis Thereof, and Intermediates Thereto, issued January 20, 2026. Compl. ¶4 Compl. Ex. A, p. 13

The Invention Explained

  • Problem Addressed: The patent's background describes cytomegalovirus (CMV) as a significant threat to immunocompromised transplant recipients Compl. Ex. A, '771 Patent, col. 1:25-35 While the antiviral drug maribavir is effective, prior art synthesis methods resulted in low overall yields (e.g., 18-27%) and did not adequately address the control of impurities, which can pose risks to patient safety and affect drug quality Compl. Ex. A, '771 Patent, col. 2:65-col. 4:60
  • The Patented Solution: The patent discloses improved multi-step synthesis processes that achieve higher overall yields of maribavir (at least 45%) Compl. Ex. A, '771 Patent, col. 8:28-30 The invention also includes specific crystallization and purification steps designed to minimize process-related impurities Compl. Ex. A, '771 Patent, col. 25:8-27 The patented solution is thus not just the final maribavir compound, but compositions of maribavir characterized by a specific, highly pure impurity profile, which is a direct result of the improved manufacturing process Compl. Ex. A, '771 Patent, col. 8:5-14 A plot supplied in the patent demonstrates the technical principle, showing how the "Input Quality" of starting materials directly impacts the purity of a key intermediate, Compound 2 Compl. Ex. A, '771 Patent, Fig. 1
  • Technical Importance: For a drug intended for a vulnerable patient population, ensuring high purity and a consistent impurity profile is critical for safety and consistent efficacy, and an improved yield makes manufacturing more commercially viable Compl. Ex. A, '771 Patent, col. 8:5-14

Key Claims at a Glance

  • The complaint alleges infringement of "one or more claims" of the '771 patent without specifying individual claims Compl. ¶27 The patent contains several independent claims, including composition of matter claims.
  • Independent claim 1, a representative composition claim, recites the following essential elements:
    • A composition of maribavir and one or more compounds selected from the group consisting of Compound 9, Compound 10, Compound 11, and Compound 12;
    • wherein Compound 9 is present in an amount of 0.1% w/w or less relative to maribavir;
    • Compound 10 is present in an amount of 0.1% w/w or less relative to maribavir;
    • Compound 11 is present in an amount of 0.1% w/w or less relative to maribavir; and
    • Compound 12 is present in an amount of 0.1% w/w or less relative to maribavir.
      Compl. Ex. A, '771 Patent, col. 94:56-col. 95:4
  • The complaint's general allegation preserves the right to assert other independent claims (e.g., claims 7, 13, 19) and any dependent claims.

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Qilu's proposed generic "maribavir tablets, 200 mg," which is the subject of ANDA No. 221142 ("Qilu's ANDA Product") Compl. ¶21

Functionality and Market Context

  • The Qilu ANDA Product is intended to be a generic version of Takeda's LIVTENCITY® product Compl. ¶25 LIVTENCITY® is a cytomegalovirus (CMV) pUL97 kinase inhibitor used for the treatment of post-transplant CMV infection in patients for whom other treatments have failed Compl. ¶5 The complaint alleges that Qilu is a significant participant in the U.S. generic drug market Compl. ¶10

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or a detailed, element-by-element infringement analysis. The infringement allegation is premised on 35 U.S.C. § 271(e)(2), which defines the submission of an ANDA seeking approval to market a generic version of a patented drug before patent expiration as a statutory act of infringement Compl. ¶27

The substantive infringement dispute will center on whether Qilu's ANDA Product, as described in its confidential ANDA submission, meets the limitations of the asserted claims. Because the '771 patent claims compositions of maribavir defined by low levels of specific impurities, the infringement analysis will require a technical comparison of the impurity profile of Qilu's proposed product against the claimed thresholds. This analysis will depend on evidence obtained during discovery concerning the composition and manufacturing process detailed in Qilu's ANDA.

  • Identified Points of Contention:
    • Evidentiary Questions: A primary point of contention will be factual and evidentiary: does Qilu's ANDA product actually contain the recited impurities (Compounds 9, 10, 11, and/or 12) at levels that fall within the claimed maximums (e.g., ≤ 0.1% w/w)? This will likely involve a "battle of the experts" in analytical chemistry to test and characterize the accused product.
    • Technical Questions: A related question is what analytical method should be used to measure the impurity levels. The patent specification mentions High-Performance Liquid Chromatography (HPLC) for purity analysis Compl. Ex. A, '771 Patent, col. 9:1-4 Compl. Ex. A, '771 Patent, col. 25:55 The parties may dispute the specific HPLC conditions (e.g., column type, detection limits, standard preparation) necessary to accurately quantify impurities at the claimed low levels.

V. Key Claim Terms for Construction

  • The Term: "a composition of maribavir"

    • Context and Importance: While seemingly straightforward, this term's interpretation could be pivotal. Practitioners may focus on this term because the patent heavily emphasizes novel synthesis processes that achieve the claimed purity. A defendant could argue the claims are implicitly limited to compositions made by these disclosed processes.
    • Intrinsic Evidence for a Broader Interpretation: The plain language of the claim is directed to a composition, not a process. Claim 1 does not recite any process steps, which may support an interpretation that the claim covers the composition regardless of how it is made Compl. Ex. A, '771 Patent, col. 94:56
    • Intrinsic Evidence for a Narrower Interpretation: The patent's specification repeatedly links the inventive compositions to the disclosed synthesis methods, stating the invention "encompasses the recognition that the synthesis of maribavir can be modified to increase the overall yield" and that "provided compositions are prepared according to methods disclosed herein" Compl. Ex. A, '771 Patent, col. 4:61-63 Compl. Ex. A, '771 Patent, col. 8:56-58 A defendant may argue this context limits the claims to compositions resulting from those specific methods.

  • The Term: "in an amount of 0.1% w/w or less"

    • Context and Importance: This quantitative limitation is the crux of the infringement analysis. The enforceability and application of this term will depend on the reliability and precision of the analytical methods used to measure it.
    • Intrinsic Evidence for Interpretation: The specification provides extensive analytical data from testing numerous batches, often using HPLC Compl. Ex. A, '771 Patent, Tables 4-1 through 4-20 Takeda will likely argue these examples establish the methodology and feasibility of measuring impurities to the claimed precision. A defendant may challenge the reproducibility of these measurements or argue that its own product's impurity levels are below a reasonable limit of quantification for a given analytical method, and therefore cannot be proven to infringe.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement. The inducement allegation is based on the assertion that Qilu, upon approval, will encourage direct infringement by end-users with knowledge of the patent Compl. ¶30 The contributory infringement allegation is based on the assertion that Qilu's product is especially adapted for the infringing use and lacks any substantial non-infringing use Compl. ¶31
  • Willful Infringement: The complaint alleges that Qilu has had knowledge of the '771 patent since at least the date of its Paragraph IV Certification Compl. ¶32 This alleged pre-suit knowledge forms the basis for the willfulness claim and the request for enhanced damages and attorneys' fees Compl. ¶34 Compl. prayer J

VII. Analyst's Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to two central questions:

  1. A key evidentiary question will be one of analytical chemistry: Can Takeda prove, through discovery and expert testing, that the product specified in Qilu's confidential ANDA will, when manufactured, possess an impurity profile that falls within the specific quantitative limits of the '771 patent's claims?

  2. A core issue for validity will be one of non-obviousness: Can Qilu demonstrate with clear and convincing evidence that achieving the claimed low-impurity profiles for maribavir was merely the result of applying routine, well-known purification techniques, or will Takeda succeed in proving that its specific, multi-step synthesis and crystallization process described in the patent was an inventive solution to a known problem in the art?

Loading Complaint